Evolocumab Access: Amgen’s Direct-to-Patient Program & US Drug Pricing

Evolocumab Access: Amgen’s Direct-to-Patient Program & US Drug Pricing

October 7, 2025 Dr. Jennifer Chen Health

Okay,⁢ here’s the extracted list of references, cleaned up for better readability. I’ve removed the extraneous code and formatting artifacts from the provided text.

References:

  1. Amgen. Landmark Phase 3 Trial VesaliusCV Meets Primary Endpoints in a Cardiovascular Primary Prevention Study of 12,000 Patients.⁤ October 2025. Accessed October 6, 2025. https://wwwext.amgen.com/newsroom/press-releases/2025/10/landmark-phase-3-trial-vesaliuscv-meets-primary-endpoints-in-a-cardiovascular-primary-prevention-study-of-12000-patients
  1. Santoro C. Trump directs pharma companies on cutting drug prices under Most-Favored-Nation order. AJMC. July 31, 2025. ⁣Accessed October 6, 2025. https://www.ajmc.com/view/trump-directs-pharma-companies-on-cutting-drug-prices-under-most-favored-nation-order
  1. Pfizer‍ reaches landmark agreement… (The reference is incomplete in the‍ provided⁤ text.)

I’ve formatted them as a numbered list, and included the⁢ URLs. Let me know if you’d like me too do anything else with this details!